PDL licenses undisclosed CoGenesys target antigen to develop antibody therapeutics

By E. Janene Geiss

Philadelphia, Jan. 10 - CoGenesys, a division of Human Genome Sciences Inc., and PDL BioPharma, Inc. announced Tuesday a worldwide licensing agreement that provides PDL certain exclusive rights to intellectual property for an undisclosed target antigen discovered by Human Genome Sciences.

Under the agreement, CoGenesys is entitled to an upfront licensing fee, development milestone payments and royalties on future sales of antibody therapeutics developed by PDL against the target, according to a company news release.

PDL also will provide CoGenesys with access to its antibody humanization technology platform. Additional terms were not disclosed, officials said.

"We are delighted to partner with CoGenesys to enable further development of this novel preclinical therapeutic program," said Richard Murray, senior vice president, chief scientific and technical officer of PDL, in the release.

PDL is a Fremont, Calif., biopharmaceutical company focused on developing and commercializing new therapies for severe or life-threatening illnesses.

Human Genome is a Rockville, Md., biopharmaceutical company focused on developing, manufacturing and marketing new therapeutics with a primary focus on protein and antibody drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.